If you live with polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF), you may have heard your doctor mention your “mutation” or “allele burden.” A new review takes a close look at MRD monitoring in MPN, and I want to walk you through it in plain language. The review, by Gary Markey and Stephen […]
FDA Approves BESREMi for Essential Thrombocythemia (ET)
By David Wallace | September 13, 2026 The FDA approved BESREMi for essential thrombocythemia on August 31, 2026, giving adults with ET their first new FDA-approved treatment in nearly 30 years. BESREMi (ropeginterferon alfa-2b-njft) is a long-acting interferon given by injection every two weeks. If hydroxyurea is not controlling your disease or its side effects […]
New Scoring Model Improves Prediction of Outcomes in Essential Thrombocythemia
by David Wallace Summary: Researchers have developed a new Essential Thrombocythemia scoring system called the “triple A” (AAA) model to predict outcomes in patients with essential thrombocythemia (ET), a type of blood cancer. This model uses three simple factors: age, absolute neutrophil count, and absolute lymphocyte count to categorize patients into different risk groups. The […]
September is Blood Cancer Awareness Month for MPNs
by Lou Ann Donovan and David Wallace National Blood Cancer Awareness Month: Spotlight on Myeloproliferative Neoplasms September marks National Blood Cancer Awareness Month, an annual event established by Congress in 2010 to shed light on various blood diseases, including the lesser-known chronic blood cancers called Myeloproliferative Neoplasms (MPNs). The statistics are sobering: every three minutes, […]
